540 GAITHER ROAD, ROCKVILLE, MD
Board Appointment - Ron Philip Joins Avalo Therapeutics Board
Investor Presentation
Material Contracts, News
Reports First Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics Enters Underwriting Agreement for $350 Million Offering
Purchases Optional Milestone Buyout
Annual Report to Security Holders
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report